Skip to content

The efficacy and mechanism of an integrated mindfulness-based programme on posttraumatic stress disorder among people with HIV: a randomized controlled trial with 3-month follow up.

Chulei Tang, Ting Zhao, Simin Yu, Yanfei Jin, Honghong Wang

European Journal of Psychotraumatology January 19, 2026 DOI: 10.1080/20008066.2025.2602298 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 82
Population People with HIV and PTSD
Intervention Integrated Mindfulness-Based Programme (IMBP)
Duration 3-month follow-up
Topics Meditation PTSD
Keywords Hiv/aids Posttraumatic stress disorder Vih/sida Community resiliency model Mindfulness-based stress reduction Randomized controlled trial
Key findings The integrated mindfulness-based programme reduced PTSD symptoms and improved ART adherence in people with HIV, with effects sustained at three months.

Abstract

Background: Posttraumatic stress disorder (PTSD) is highly prevalent among people with HIV (PWH) and is associated with poor psychological functioning and reduced adherence to antiretroviral therapy (ART), threatening treatment outcomes. Although the Community Resiliency Model (CRM) and mindfulness-based stress reduction (MBSR) have separately demonstrated efficacy for PTSD, no intervention integrating these approaches has been specifically developed for PWH.Objective: This study aimed to evaluate the efficacy and mechanisms of an Integrated Mindfulness-Based Programme (IMBP), combining CRM and MBSR, in reducing PTSD symptoms and enhancing ART adherence among PWH.Methods: Eighty-two PWH with PTSD were assigned to either the IMBP intervention group or the control group. PTSD symptoms and ART adherence were assessed at baseline, post-intervention, and 3-month follow-up. Mindfulness, rumination, and resilience were evaluated as potential mediators. Data were analyzed using generalized estimating equations (GEE) and mediation modelling.Results: Compared with the control group, participants receiving IMBP demonstrated significantly greater reductions in PTSD symptoms and improvements in ART adherence, both immediately post-intervention and at 3-month follow-up (all p < .01). Mediation analysis revealed that increased mindfulness, enhanced resilience, and decreased rumination partially mediated the effect of the intervention on PTSD symptoms.Conclusion: The IMBP intervention was effective in reducing PTSD symptoms as well as improving ART adherence in PWH. The mediating roles of mindfulness, resilience, and rumination suggest plausible mechanisms through which the intervention operates. These findings support the clinical utility of IMBP as a low-resource intervention for addressing the dual challenges of trauma and treatment adherence in vulnerable HIV-positive populations.

Comparable studies

Other randomized controlled trials on PTSD, most cited first.

Study Year Design Participants
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Patients with severe PTSD, including those with comorbidities such as dissociation,... 2021 Randomized controlled trial n = 90
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Patients with chronic post-traumatic stress disorder refractory to both psychotherapy... 2010 Randomized controlled trial n = 20
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder Patients with chronic PTSD related to a range of trauma exposures 2014 Randomized controlled trial n = 41
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Military veterans and first responders aged 18 or older with chronic PTSD lasting 6... 2018 Randomized, double-blind, dose-response, phase 2 clinical trial n = 26
A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) Patients with treatment-resistant PTSD 2012 Randomized controlled trial n = 12

Citations in the library

Explore topics